BCL2L1 and cancer: Therefore, to reverse the sensitivity of Bcl‐xL dependent‐resistant cancer cells or to attain cell‐selectivity towards Bcl‐xL over‐expressed senescent/cancer cells requires a Bcl‐xL inhibitor devoid of platelet toxicity.